uniQure N.V. (NASDAQ:QURE) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of uniQure N.V. (NASDAQ:QURE) have been assigned an average recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $60.8182.

A number of brokerages have recently weighed in on QURE. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, October 8th. Benchmark restated a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. Royal Bank Of Canada cut their target price on uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research note on Monday, November 3rd. Wells Fargo & Company reduced their price target on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. Finally, HC Wainwright dropped their price objective on shares of uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th.

Insider Activity at uniQure

In related news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the sale, the director directly owned 20,439 shares in the company, valued at $557,575.92. This trade represents a 23.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the sale, the director directly owned 32,342 shares in the company, valued at $796,260.04. The trade was a 44.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 102,247 shares of company stock worth $2,839,298 in the last 90 days. 4.79% of the stock is owned by company insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Private Trust Co. NA bought a new position in uniQure in the 3rd quarter valued at about $28,000. Jones Financial Companies Lllp raised its position in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure in the 3rd quarter worth approximately $50,000. FNY Investment Advisers LLC boosted its holdings in shares of uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 718 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 5,538 shares during the period. 78.83% of the stock is currently owned by institutional investors.

uniQure Trading Up 3.9%

uniQure stock opened at $22.84 on Monday. uniQure has a 1 year low of $7.76 and a 1 year high of $71.50. The firm’s 50-day moving average is $24.77 and its 200-day moving average is $27.91. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The company has a market cap of $1.42 billion, a P/E ratio of -5.20 and a beta of 0.68.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. On average, equities analysts expect that uniQure will post -3.75 earnings per share for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.